- Home
- ALLO vs BRSP Comparison
ALLO vs BRSP Comparison
Compare ALLO & BRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLO | BRSP |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 452.6M | 528.9M |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ALLO | BRSP |
|---|---|---|
| Price | $1.25 | $3.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $9.00 | $5.97 |
| AVG Volume (30 Days) | ★ 5.3M | 1.8M |
| Earning Date | 11-05-2026 | 10-27-2026 |
| Dividend Yield | N/A | ★ 17.53% |
| EPS Growth | 34.09 | ★ 75.24 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $330,587,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $255.46 | $0.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $3.56 |
| 52 Week High | $4.46 | $6.17 |
Technical Indicators
Market Signals| Indicator | ALLO | BRSP |
|---|---|---|
| Relative Strength Index (RSI) | 25.84 | 33.41 |
| Support Level | $1.22 | N/A |
| Resistance Level | $2.22 | $3.94 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 25.00 | 30.26 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.